A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)

NCT03217812 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

220

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Velcade
DRUG: Melphalan
DRUG: Prednisone
DRUG: Daratumumab

Sponsor

Janssen Research & Development, LLC